Drug intelligence / Profile preview

Metamizole sodium

Development stage
Phase 4
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Rectal
01

Overview

Metamizole sodium is a non-opioid analgesic, antipyretic, and spasmolytic medication that has been in use since the 1920s. Despite being widely available in many countries worldwide, it has been banned in several countries including the United States due to safety concerns. ## Pharmacology and Uses Metamizole sodium works as a potent pain reliever, fever reducer, and muscle spasm relaxant. It's commonly used for: - Moderate to severe pain (including postoperative pain) - Pain from cancer - Migraine headaches - Gastrointestinal tract pain - High fever unresponsive to other agents - Biliary and intestinal colic-like pain The medication can be administered orally, intravenously, intramuscularly, or as a suppository, with dosing typically ranging from 500-1000 mg up to 3-4 times daily for adults, with a maximum daily dose of 4000 mg. ## Safety Profile and Restrictions The most significant safety concern with metamizole sodium is its association with agranulocytosis, a potentially life-threatening blood disorder characterized by a severe decrease in white blood cell counts. This risk has led to its ban in several countries including the United States, United Kingdom, Japan, Canada, and parts of Europe. Other side effects include: - Low blood pressure - Chest pain and arrhythmias - Nausea and upset stomach - Dizziness - Kidney problems - Shortness of breath - Rash - Rare but serious reactions like anaphylaxis and Stevens-Johnson syndrome Recent concerns about liver injury have also emerged, with cases ranging from mild to severe, including some fatalities.

Brand names
NovalginAnalginNeo-MelubrinaOptalginAlgocalminAlgozoneDimethoneProtempPyralginNeosaldinaSedalginaDoridinaMigranetteBenegripAnadorMagnopyrolConmel
Other names
Metamizolum natricumMetamizol sodium hydrateMetamizole sodium monohydrateSulpyrineDipirona
02

Targets

KATP channel (ATP-sensitive potassium channel)CNR1 (Cannabinoid receptor 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)IP3R (Inositol Trisphosphate Receptor)

Beyond the preview

Go deeper on Metamizole sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metamizole sodium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call